ODAN-PROPARACAINE 0.5 % — DIN 00622974
PROPARACAINE HYDROCHLORIDE : 0.5 % · ODAN LABORATORIES LTD · SOLUTION · wholesale supply in Canada
Health Canada status: DORMANT
What is ODAN-PROPARACAINE?
ODAN-PROPARACAINE 0.5 % contains PROPARACAINE HYDROCHLORIDE : 0.5 %. It is listed in the Health Canada Drug Product Database under DIN 00622974, held by ODAN LABORATORIES LTD, supplied as SOLUTION for OPHTHALMIC administration. Health Canada currently lists it as dormant, status dated 22-Jun-2017. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ODAN-PROPARACAINE used for?
Topical anesthesia for ophthalmic procedures (tonometry, removal of foreign bodies/sutures, conjunctival scraping, gonioscopic examination) and prior to surgery (cataract extraction).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Proxymetacaine in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Proxymetacaine, across 6 DINs, of which 1 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ALCON CANADA INC | 1 | 1 | ALCAINE | Sourceable in Canada |
| ALLERGAN INC | 1 | 0 | OPHTHETIC | No marketed DIN |
| ODAN LABORATORIES LTD | 1 | 0 | ODAN-PROPARACAINE | No marketed DIN |
| PHARMA STULLN INC. | 1 | 0 | PROPARACAINE | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-PROPARACAINE HYDROCHLORIDE OPH SOLTN 0.5% | No marketed DIN |
| RICHMOND PHARMACEUTICALS INC. | 1 | 0 | R.O.-PARCAINE DPS 5MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.5 % |
|---|---|
| Dosage form | SOLUTION |
| Route | OPHTHALMIC |
| Pack configuration (monograph) | 15 mL plastic dropper container. |
| Storage | Store at 2°C - 8°C. Keep refrigerated. Do not use if solution is darker than pale yellow. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Substance and classification
| Active substance | Proxymetacaine |
|---|---|
| ATC code | S01HA04 |
| AHFS class | 52:16.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00622974 |
|---|---|
| DIN (unpadded, as printed on some documents) | 622974 |
| Brand name | ODAN-PROPARACAINE |
| Generic / active ingredient | PROPARACAINE HYDROCHLORIDE : 0.5 % |
| Market authorization holder | ODAN LABORATORIES LTD |
| Health Canada schedule | Ethical |
| ATC code | S01HA04 |
| ATC anatomical main group | S — Sensory organs |
| ATC therapeutic subgroup | S01HA |
| Current status | DORMANT |
| Status date | 22-Jun-2017 |
| Original market date | 1985-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Cataract extraction: 1 drop every 5-10 mins (5-7 doses). Suture removal: 1-2 drops 2-3 mins before. Foreign bodies: 1-2 drops. Tonometry: 1-2 drops immediately before.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to proparacaine or any ingredient. Should never be prescribed for the patient’s own use.
Warnings and precautions
For professional use only. Prolonged use may lead to corneal epithelial toxicity, permanent corneal damage, and delayed wound healing. Avoid touching eye until anesthesia wears off.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
1 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALCAINE | 0.5 % | DROPS | ALCON CANADA INC | MARKETED | 00035076 |
| OPHTHETIC | .5 % | DROPS | ALLERGAN INC | CANCELLED POST MARKET | 00001279 |
| PMS-PROPARACAINE HYDROCHLORIDE OPH SOLTN 0.5% | .5 % | DROPS | PHARMASCIENCE INC | CANCELLED POST MARKET | 00872857 |
| PROPARACAINE | 0.5 % | SOLUTION | PHARMA STULLN INC. | DORMANT | 02023652 |
| R.O.-PARCAINE DPS 5MG/ML | 5 MG | DROPS | RICHMOND PHARMACEUTICALS INC. | CANCELLED POST MARKET | 02003961 |
2 · Same class — other molecules in ATC S01HA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Tetracaine | MINIMS TETRACAINE HYDROCHLORIDE · PONTOCAINE 5 MG/ML · PONTOCAINE DPS 0.5% | 4 | 2 | Yes |
| Proxymetacaine | ALCAINE · ODAN-PROPARACAINE · OPHTHETIC · PMS-PROPARACAINE HYDROCHLORIDE OPH SOLTN 0.5% · +2 more | 6 | 1 | Yes |
| Oxybuprocaine | MINIMS BENOXINATE HYDROCHLORIDE 0.4% | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.